About: Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats
Creator	Norris, Jacqueline Govendir Id, Merran Kimble, Benjamin Izes, Aaron
Source	Medline; PMC
abstract	The antimalarial agent mefloquine is currently being investigated for its potential to inhibit feline coronavirus and feline calicivirus infections. A simple, high pressure liquid chromatography assay was developed to detect mefloquine plasma concentrations in feline plasma. The assay’s lower limit of quantification was 250 ng/mL. The mean ± standard deviation intra- and inter-day precision expressed as coefficients of variation were 6.83 ± 1.75 and 5.33 ± 1.37%, respectively, whereas intra- and inter-day accuracy expressed as a percentage of the bias were 11.40 ± 3.73 and 10.59 ± 3.88%, respectively. Accordingly, this validated assay should prove valuable for future in vivo clinical trials of mefloquine as an antiviral agent against feline coronavirus and feline calicivirus. However, the proportion of mefloquine binding to feline plasma proteins has not been reported. The proportion of drug bound to plasma protein binding is an important concept when developing drug dosing regimens. As cats with feline infectious peritonitis (FIP) demonstrate altered concentrations of plasma proteins, the proportion of mefloquine binding to plasma proteins in both clinically normal cats and FIP-affected cats was also investigated. An in vitro method using rapid equilibrium dialysis demonstrated that mefloquine was highly plasma protein bound in both populations (on average > 99%).
has issue date	2020-08-05(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0236754
bibo:pmid	32756590
has license	cc-by
sha1sum (hex)	53ca6f2d105237275744c0d8bc7218c30dfd0992
schema:url	https://doi.org/10.1371/journal.pone.0236754
resource representing a document's title	Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats
has PubMed Central identifier	PMC7406051
has PubMed identifier	32756590
schema:publication	PLoS One
resource representing a document's body	covid:53ca6f2d105237275744c0d8bc7218c30dfd0992#body_text
is schema:about of	named entity 'average' named entity 'bias' named entity 'altered' named entity 'plasma protein binding' named entity 'normal' named entity 'proteins' named entity 'demonstrate' named entity 'precision' named entity 'assay' named entity 'FIP' named entity 'populations' named entity 'feline calicivirus' named entity 'agent' named entity 'simple' named entity 'proteins' named entity 'cats' named entity 'mefloquine' named entity 'binding' named entity 'plasma' named entity 'coefficients of variation' named entity 'mefloquine' named entity 'mefloquine' named entity 'dialysis' named entity 'assay' named entity 'plasma proteins' named entity 'binding to plasma proteins' named entity 'FIP' named entity 'FIP' named entity 'mefloquine' named entity 'FIPV' named entity 'PLOS ONE' named entity 'FIP' named entity 'significant difference' named entity 'PPB' named entity 'Thornleigh' named entity 'Mefloquine' named entity 'plasma' named entity 'plasma protein binding' named entity 'albumin' named entity 'limit of quantification' named entity 'mefloquine' named entity 'accuracy and precision' named entity 'falciparum malaria' named entity 'mefloquine' named entity 'significant difference' named entity 'methanol' named entity 'liquid chromatography' named entity 'verapamil' named entity '5.0' named entity '14.5' named entity 'feline infectious peritonitis virus' named entity 'plasma' named entity 'plasma' named entity 'mechanism of action' named entity 'endogenous' named entity 'routine vaccinations' named entity 'plasma' named entity 'quality control' named entity 'broad spectrum' named entity 'pharmacokinetic profile' named entity 'Sigma-Aldrich' named entity 'FIP' named entity 'mefloquine' named entity 'sildenafil' named entity 'FIP' named entity 'antiviral medications' named entity 'plasma protein bound' named entity 'plasma protein binding' named entity 'normal distribution' named entity 'FIP' named entity 'pH 7' named entity '220 nm' named entity 'FIP' named entity 'analyte' named entity 'body temperature' named entity 'plasma' named entity 'plasma' named entity 'protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software